Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Featured Story

After setback, Sanofi, GSK take tweaked COVID-19 vaccine into phase 2

By Nick Paul Taylor

Sanofi and GlaxoSmithKline have begun a phase 2 clinical trial of a new version of their adjuvanted recombinant protein-based COVID-19 vaccine candidate. The study start comes around two months after weak clinical data forced the partners to rethink the antigen formulation.

COVID-19 costs, care deferrals came back to bite insurers in Q4 2020

By Paige Minemyer

Rising costs related to COVID-19 and more stable care utilization dinged payers' finances in the fourth quarter.

After Pfizer deal, Sanofi offers a hand to Johnson & Johnson for COVID-19 vaccine production

By Eric Sagonowsky

Sanofi hasn't abandoned its COVID-19 vaccine hopes despite a setback in the high-stakes race, but as it moves two separate technologies forward, it's also pitching in to make vaccines for its usual rivals. The deal is the latest pandemic tie-up among Big Pharma companies.

AstraZeneca's Indian COVID-19 vaccine partner told to prioritize local supplies: CEO

By Fraiser Kansteiner

Serum Institute of India has been told to focus on India's domestic vaccine needs first, CEO Adar Poonawalla said, urging patience as the company balances the massive demand in its home country with established supply pacts. The move could slow deliveries of AstraZeneca's shot outside India, including to Europe.

Kaufman Hall: COVID-19 hospitalizations down in January but revenue also in decline

By Robert King

COVID-19 hospitalizations tapered off in the second half of January after major surges last fall and winter, but revenues remain down, a new report from Kaufman Hall said.

BD to develop smartphone-powered home COVID test with Scanwell Health

By Conor Hale

BD has begun working with the digital home testing company Scanwell Health, to pair up the former’s rapid antigen diagnostic for COVID-19 with the latter’s smartphone platform.

Eli Lilly CEO's pay grows—again—to $23.7M after COVID antibody launch, new approvals

By Eric Sagonowsky

The COVID-19 pandemic derailed plans for companies worldwide last year, but Eli Lilly adapted by developing medicines against the novel coronavirus—to the tune of $871 million in Q4—while still pushing sales of its newer meds. Now, CEO David Ricks has posted a pay package that could place him among the best-compensated pharma CEOs of the year.

Healthcare roundup—Transplant patient dies after receiving COVID-infected lungs

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

Biopharma roundup—Gottlieb says U.S. may not hit herd immunity

By Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Conor Hale

Sanofi struck a deal with to produce Johnson & Johnson COVID-19 vaccines. It also announced the start of a phase 2 trial of its own vaccine, developed with GSK. Eli Lilly CEO David Ricks earned $23.7 million, reflecting the success of the company in 2020.

COVID-19 Tracker